126 related articles for article (PubMed ID: 29061781)
1. Probing the Oncolytic and Chemosensitizing Effects of Dihydrotanshinone in an
Kumar V; Radin D; Leonardi D
Anticancer Res; 2017 Nov; 37(11):6025-6030. PubMed ID: 29061781
[TBL] [Abstract][Full Text] [Related]
2. Studies examining the synergy between Dihydrotanshinone and Temozolomide against MGMT+ glioblastoma cells in vitro: Predicting interactions with the blood-brain barrier.
Kumar V; Radin D; Leonardi D
Biomed Pharmacother; 2019 Jan; 109():386-390. PubMed ID: 30399573
[TBL] [Abstract][Full Text] [Related]
3. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
Aghi M; Rabkin S; Martuza RL
J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370
[TBL] [Abstract][Full Text] [Related]
4. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression.
Kohsaka S; Wang L; Yachi K; Mahabir R; Narita T; Itoh T; Tanino M; Kimura T; Nishihara H; Tanaka S
Mol Cancer Ther; 2012 Jun; 11(6):1289-99. PubMed ID: 22532597
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
6. JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.
Okada M; Sato A; Shibuya K; Watanabe E; Seino S; Suzuki S; Seino M; Narita Y; Shibui S; Kayama T; Kitanaka C
Int J Oncol; 2014 Feb; 44(2):591-9. PubMed ID: 24316756
[TBL] [Abstract][Full Text] [Related]
7. N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death.
Zhang J; Hummersone M; Matthews CS; Stevens MF; Bradshaw TD
Oncology; 2015; 88(1):28-48. PubMed ID: 25277441
[TBL] [Abstract][Full Text] [Related]
8. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
9. Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51.
Xipell E; Aragón T; Martínez-Velez N; Vera B; Idoate MA; Martínez-Irujo JJ; Garzón AG; Gonzalez-Huarriz M; Acanda AM; Jones C; Lang FF; Fueyo J; Gomez-Manzano C; Alonso MM
Neuro Oncol; 2016 Aug; 18(8):1109-19. PubMed ID: 26951384
[TBL] [Abstract][Full Text] [Related]
10. Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma.
Wagner LM; McLendon RE; Yoon KJ; Weiss BD; Billups CA; Danks MK
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5418-25. PubMed ID: 17875772
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C
PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477
[TBL] [Abstract][Full Text] [Related]
12. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
[TBL] [Abstract][Full Text] [Related]
13. Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.
Stritzelberger J; Distel L; Buslei R; Fietkau R; Putz F
Clin Transl Oncol; 2018 Apr; 20(4):508-516. PubMed ID: 28825189
[TBL] [Abstract][Full Text] [Related]
14. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.
Clark PA; Gaal JT; Strebe JK; Pasch CA; Deming DA; Kuo JS; Robins HI
J Clin Neurosci; 2017 Feb; 36():120-124. PubMed ID: 27865821
[TBL] [Abstract][Full Text] [Related]
15. Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.
Lan F; Pan Q; Yu H; Yue X
J Neurochem; 2015 Sep; 134(5):811-8. PubMed ID: 25991372
[TBL] [Abstract][Full Text] [Related]
16. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
[TBL] [Abstract][Full Text] [Related]
17. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
18. A steroidal saponin form Paris vietnamensis (Takht.) reverses temozolomide resistance in glioblastoma cells via inducing apoptosis through ROS/PI3K/Akt pathway.
Zhang S; Lu Y; Li H; Ji Y; Fang F; Tang H; Qiu P
Biosci Trends; 2020 May; 14(2):123-133. PubMed ID: 32173672
[TBL] [Abstract][Full Text] [Related]
19. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X
Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123
[TBL] [Abstract][Full Text] [Related]
20. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
Sato A; Sunayama J; Matsuda K; Seino S; Suzuki K; Watanabe E; Tachibana K; Tomiyama A; Kayama T; Kitanaka C
Stem Cells; 2011 Dec; 29(12):1942-51. PubMed ID: 21957016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
